Year Founded
1999
Ownership
Public
Employees
~104
Therapeutic Areas
Ophthalmology
Stage
Phase 2
Modalities
Gene therapy

Applied Genetic Technologies General Information

Applied Genetic Technologies Corp. (AGTC) is advancing its lead gene therapy candidate, AGTC-501, for X-linked retinitis pigmentosa (XLRP). The company has exceeded enrollment targets for its SKYLINE trial and reported promising interim results, including improvements in visual sensitivity and visual acuity. AGTC-501 has demonstrated safety and tolerability across all doses in clinical trials.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Alachua, Florida
United States

Drug Pipeline

laruparetigene zosaparvovec
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Applied Genetic Technologies's pipeline data

Book a demo

Key Partnerships

Biogen

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Applied Genetic Technologies Funding

Deal TypeDateAmountStatusStage
Later Stage VCJul 12, 2022$10.0MCompletedPhase 2
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Applied Genetic Technologies's complete valuation and funding history, request access »